Migraine sufferers could receive a daily pill on the NHS which can slash in half the frequency of their crippling headaches.
NHS spending watchdog, the National Institute for Health and Care Excellence (NICE), will decide later this month whether to offer the drug, named atogepant, to patients who have failed to respond to other treatments.
Experts expect the pill, which costs about £8,000 a year per patient, to be approved after studies revealed that it is significantly more effective than
Pressure is mounting on the European Commission to extend a ban on select Ukrainian agricultural products as the deadline for the current temporary arrangement looms – but not everyone is in agreement.
The current temporary ban on select Ukrainian agricultural goods, which expires on 15 September, was put in place to appease frontline countries who unilaterally imposed their own ban back in April after an influx of Ukrainian agricultural products put pressure on their farmers.
Amid concerns the recent collapse
